摘要Breast cancer remains a global health challenge with greater than 2.3 million new cases diagnosed annually 1,according to the World Health Organization1.Management of breast cancer is shaped by a complex interplay of international guidelines,regional adaptations,and the rapidly evolving fields of precision medicine and artificial intelligence(AI).International guide-lines and consensus statements,such as those from the National Comprehensive Cancer Network(NCCN)2,the European Society for Medical Oncology(ESMO)3,4,and the St.Gallen International Breast Cancer Conference5,provide a framework for standardized care.However,these frameworks must accom-modate clinical heterogeneity across diverse populations,while integrating cutting-edge advances in precision medicine and AI to achieve what is termed"intelligent standardization."This editorial explores how global guidelines inform region-spe-cific practices,the transformative impact of precision medicine through molecular subtyping and biomarker-driven therapies,and the emerging role of AI in enhancing diagnostic accuracy,treatment decision-making,and patient stratification.